Related Experiment Videos
High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia
Stephan M Feller1, Gabriele Tuchscherer, Jan Voss
1Cell Signalling Group, Molecular Oncology Laboratory, Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. stephan.feller@.cancer.org.uk
Abstract:
Chronic myelogenous leukaemia (CML) is one of the most intensively studied human malignancies. It has been the focus of major efforts to develop potent drugs for several decades, but until recently cure rates remained low. A breakthrough in CML therapy was very likely accomplished with the clinical introduction of STI-571 [imatinib mesylate; Gleevec (USA); Glivec (other countries)] in 2000/2001. Despite the hope that STI-571 has generated for many CML patients, development of resistance to this drug is already apparent in some cases, especially if the CML is diagnosed in its later stages. Therefore, novel drugs which can be used alone or in combination with STI-571 are highly desirable. This review briefly summarises the current understanding and therapy of CML and then discusses in more detail basic laboratory research that attempts to target Grb2, an adaptor protein known to directly interact with the Bcr portion of the Bcr-Abl fusion protein. Blocking the binding of Grb2 to the GDP-releasing protein SoS is well known to abrogate the activation of the GTPase Ras, a major driving force of the central mitogenic (MAP kinase) pathway. Additional Grb2 effector proteins may also contribute to the proliferation-inhibiting effects observed upon uncoupling Grb2 from its downstream signalling system. Since Grb2 is a known signal transducer for several major human oncogenes, this approach may have applications for a wider range of human cancers.
Insights
Novel drugs targeting the Grb2 protein may overcome resistance to imatinib mesylate in chronic myelogenous leukemia (CML). This approach could also benefit other cancers by inhibiting key cell proliferation pathways.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Chronic myelogenous leukemia (CML) is a significant human malignancy with limited treatment options until imatinib mesylate (STI-571).
- Imatinib resistance is emerging, particularly in advanced CML stages, necessitating alternative therapeutic strategies.
- The Bcr-Abl fusion protein is a key driver in CML pathogenesis.
Purpose of the Study:
- To review current CML understanding and therapies.
- To explore targeting the adaptor protein Grb2 as a novel therapeutic strategy for CML.
- To investigate Grb2's role in Bcr-Abl signaling and its potential for broader cancer applications.
Main Methods:
- Literature review of CML pathogenesis and therapy.
- Discussion of laboratory research targeting Grb2.
- Analysis of Grb2's interaction with Bcr-Abl and downstream signaling pathways (Ras/MAP kinase).
Main Results:
- Imatinib mesylate has revolutionized CML treatment but faces resistance challenges.
- Grb2 directly interacts with the Bcr-Abl fusion protein.
- Blocking Grb2-SoS interaction inhibits Ras GTPase activation and the MAP kinase pathway.
Conclusions:
- Targeting Grb2 offers a promising strategy to overcome imatinib resistance in CML.
- Inhibiting Grb2 signaling may provide therapeutic benefits for CML patients.
- Grb2's role in oncogenesis suggests potential applications for Grb2-targeted therapies in various human cancers.